Navigation Links
Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/8/2011

SAN DIEGO, March 8, 2011 /PRNewswire/ -- Sequenom, Inc. (Nasdaq: SQNM) today reported its financial results for the fourth quarter and the year ended December 31, 2010.

(Logo:  http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

Fourth Quarter Results

  • Total revenue for the fourth quarter of 2010 grew 28% to $13.8 million, compared with $10.8 million for the fourth quarter of 2009. The increase in revenue compared to the same period last year was primarily due to higher system and consumables sales as well as the addition of increased diagnostic revenues from testing services.
  • Net loss for the fourth quarter of 2010 was $22.0 million, or $0.27 per share, compared with $18.4 million, or $0.30 per share, for the fourth quarter of 2009. Net loss includes a $6.5 million non-cash charge recognized for the revaluation of the company's litigation settlement to a fair value of $8.03 per share for the approximately 6.4 million shares that were issued to the class members in the consolidated federal securities class actions on December 31, 2010.

  • Gross margin for the fourth quarter of 2010 was 62% compared with 50% for the fourth quarter of 2009, reflecting improved margins and changes in the mix of products sold in the company's genetic analysis segment, as well as improved margins associated with increased test volumes within the diagnostics segment at the company's wholly-owned molecular diagnostics laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM).

    Research and development (R&D) expenses were $10.5 million for the fourth quarter of 2010, compared with $10.0 million for the same period in the prior year. The increase was primarily due to Sequenom CMM's assay development and the company's clinical sample acquisition costs associated with its triso
    '/>"/>

    SOURCE Sequenom, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
    2. Sequenom Announces Paul Maier to Become Interim Chief Financial Officer
    3. Sequenom Announces Addition to Clinical Advisory Board
    4. Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit
    5. Sequenom Announces Launch of SensiGene Fetal(XY) (Fetal Sex Determination) Test
    6. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
    7. Sequenom Announces Final Approval of Settlement in Class Action Securities Lawsuit
    8. Sequenom to Present at the Jefferies 2010 Global Life Sciences Conference
    9. Sequenom Announces Date of Second Quarter 2010 Financial Results and Conference Call
    10. Sequenom to Present at Two Financial Conferences in November
    11. Sequenom CMM Commences Pivotal Clinical Validation Study for Its SensiGene Trisomy 21 Laboratory Developed Test
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
    (Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
    (Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
    Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
    (Date:7/9/2014)... signals active in almost all types of cancer sends ... may help fuel a tumour,s uncontrolled growth, new research ... London, identified a molecular trigger responsible for ratcheting up ... factory that makes the building blocks cancer cells need ... signalling pathway, called SREBP, controls the flow of messages ...
    (Date:7/9/2014)... PROVIDENCE, R.I. Researchers have found that fecal ... difficile in immunocompromised patients. This is the result ... gastroenterologist in the Center for Women,s Gastrointestinal Medicine at ... have been published online in advance of print in ... Clostridium difficile , or C. diff , has ...
    (Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
    (Date:7/9/2014)... Institute of Allergy and Infectious Diseases (NIAID), part ... an early-stage clinical trial of CRS3123, an investigational ... ( C. difficile ) infection. CRS3123 (previously ... inhibits C. difficile growth while sparing normal intestinal ... up to 30 healthy men and women ages ...
    (Date:7/9/2014)... , , , , , ... , , , , ... assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , , ...
    Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
    ... MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), a ... products, is scheduled,to announce its financial results for ... 2008, before the market opens. At 9:00 a.m. ... conference call to review the,Company,s third quarter financial ...
    ... The American Fertility Association,introduces Manicures and Martinis, ... women together in a casual setting over manicures ... preserving fertility. It,s,free, relaxing, fun, and educational. The ... hosted by leading professionals in the reproductive medical,field, ...
    ... TUCSON, Ariz., Oct. 30 NaturalNews.com, the ... one million health-conscious,consumers, has posted audio interviews ... of "Home Safe Home," and Byron Richards, ... nutritional supplement,provider. Both interviews are available as ...
    ... One of the Top 10 Most Interesting Metabolic ... 30 Genaera,Corporation (NASDAQ: GENR ) will ... held November 3-5 at the Lowes Hotel in,Philadelphia, ... Scientific Officer, will provide an overview on MSI-1436 ...
    ... are adjusted , , WEDNESDAY, Oct. 29 (HealthDay News) -- The ... it may pose problems more serious than adjusting sleep patterns. ... of heart attacks following the semi-annual one-hour time changes, although ... very first study on this topic and further studies are ...
    ... - Nuvo Research Inc.,(TSX: NRI), a Canadian drug development ... that are delivered to and through the skin,using its ... and operational results for the three and nine,months ended ... - The Company remains on target to ...
    Cached Medicine News:Health News:MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results 2Health News:The American Fertility Association Announces Plan to Help Young Women Preserve Fertility 2Health News:NaturalNews Posts Audio Interview with Consumer Chemical Expert Debra Lynn Dadd on Bisphenol-A 2Health News:Genaera to Present at Therapeutic Area Partnerships 2008 2Health News:Semi-Annual Time Changes May Affect the Heart 2Health News:Semi-Annual Time Changes May Affect the Heart 3Health News:NUVO announces third quarter 2008 financial results 2Health News:NUVO announces third quarter 2008 financial results 3Health News:NUVO announces third quarter 2008 financial results 4Health News:NUVO announces third quarter 2008 financial results 5Health News:NUVO announces third quarter 2008 financial results 6Health News:NUVO announces third quarter 2008 financial results 7Health News:NUVO announces third quarter 2008 financial results 8Health News:NUVO announces third quarter 2008 financial results 9Health News:NUVO announces third quarter 2008 financial results 10Health News:NUVO announces third quarter 2008 financial results 11Health News:NUVO announces third quarter 2008 financial results 12Health News:NUVO announces third quarter 2008 financial results 13Health News:NUVO announces third quarter 2008 financial results 14Health News:NUVO announces third quarter 2008 financial results 15
    ... The Vibratome 1500 Sectioning System provides a ... animal, or plant tissues. The 1500 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
    ... The original Vibratome Semi-Automatic Tissue Sectioning ... rock solid tissue sectioning system. Researchers from ... Vibratome 1000 Classic for their fresh and ... 20 years. With the Vibratome ...
    ... Vibratome 3000 Plus Sectioning System provides a ... animal, or plant tissues. The 3000 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
    ... Sectioning System provides a versatile means of ... tissues. The 1500 employs a vibrating ... or embedding. The creation of artifacts, ... enzyme activities, and other deleterious effect inherent ...
    Medicine Products: